a polyvalent vaccine immunotherapy for melanoma of three viable irradiated melanoma cell lines which contain at least 11 known tumor-associated antigens such as MAGE-1, MAGE-3, tyrosinase, gp100, gp75, and Mart-1/Melan-A; increased IgM response in patients receiving vaccine therapy for stage II melanoma was associated with decreased recurrence and improved survival
